- Home
- NOTE vs MAIA Comparison
NOTE vs MAIA Comparison
Compare NOTE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- MAIA
- Stock Information
- Founded
- NOTE 2013
- MAIA 2018
- Country
- NOTE United States
- MAIA United States
- Employees
- NOTE N/A
- MAIA N/A
- Industry
- NOTE EDP Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- NOTE Technology
- MAIA Health Care
- Exchange
- NOTE Nasdaq
- MAIA Nasdaq
- Market Cap
- NOTE 39.9M
- MAIA 44.9M
- IPO Year
- NOTE N/A
- MAIA 2022
- Fundamental
- Price
- NOTE $2.14
- MAIA $1.01
- Analyst Decision
- NOTE Strong Buy
- MAIA
- Analyst Count
- NOTE 4
- MAIA 0
- Target Price
- NOTE $29.25
- MAIA N/A
- AVG Volume (30 Days)
- NOTE 251.5K
- MAIA 679.2K
- Earning Date
- NOTE 11-06-2025
- MAIA 11-07-2025
- Dividend Yield
- NOTE N/A
- MAIA N/A
- EPS Growth
- NOTE N/A
- MAIA N/A
- EPS
- NOTE N/A
- MAIA N/A
- Revenue
- NOTE $102,673,000.00
- MAIA N/A
- Revenue This Year
- NOTE N/A
- MAIA N/A
- Revenue Next Year
- NOTE $4.61
- MAIA N/A
- P/E Ratio
- NOTE N/A
- MAIA N/A
- Revenue Growth
- NOTE N/A
- MAIA N/A
- 52 Week Low
- NOTE $2.05
- MAIA $0.98
- 52 Week High
- NOTE $24.36
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- NOTE 18.97
- MAIA 31.72
- Support Level
- NOTE $2.50
- MAIA $0.98
- Resistance Level
- NOTE $3.28
- MAIA $1.09
- Average True Range (ATR)
- NOTE 0.33
- MAIA 0.08
- MACD
- NOTE -0.14
- MAIA -0.01
- Stochastic Oscillator
- NOTE 7.94
- MAIA 4.77
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.